In this study, we aimed to address this clinical challenge by developing novel nomograms to predict the likelihood of PCa and clinically significant prostate cancer (csPCa) in patients with PI-RADS scores 1-3 and PSA < 10 ng/ml. The gene discussed is KLK3; the disease is posterior cortical atrophy.